Sarepta Therapeutics
Sarepta Therapeutics, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). Founded in 1980, Sarepta has achieved significant milestones, including the development of its pioneering exon-skipping therapies, which offer unique treatment options for patients with DMD. With a strong focus on advancing precision medicine, Sarepta's core products, such as eteplirsen and golodirsen, utilise cutting-edge technology to address the underlying genetic causes of muscular dystrophies. The company has established a prominent market position, recognised for its commitment to transforming the lives of patients through groundbreaking therapies. As it continues to expand its operational reach, Sarepta remains dedicated to innovation and excellence in the biotechnology industry.
DitchCarbon Score
How does Sarepta Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sarepta Therapeutics's score of 24 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sarepta Therapeutics's reported carbon emissions
In 2023, Sarepta Therapeutics reported total emissions of approximately 4,789,000 kg CO2e from Scope 1 and 2 sources. This represents a decrease from 2022, where emissions were about 5,000,000 kg CO2e for Scope 1 and approximately 3,428,000 kg CO2e for Scope 2. The company has demonstrated a commitment to reducing its carbon footprint, achieving a notable reduction in emissions from both scopes over the year. Despite these reductions, there are currently no specific reduction targets or climate pledges disclosed by Sarepta Therapeutics. The absence of formal commitments suggests that while the company is actively managing its emissions, it may not yet be aligned with industry-standard climate initiatives such as the Science Based Targets initiative (SBTi). Overall, Sarepta Therapeutics is making progress in its emissions management, but further transparency regarding long-term climate commitments would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 5,000,000 | 0,000,000 |
| Scope 2 | 3,428,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sarepta Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
